GenScript Biotech Corporation (GenScript), the world’s leading life science research tools and services provider, announced on Feb 10, 2022, the opening of a more than 30,000-square-feet facility for highly automated protein and gene preparation services.
The state-of-the-art site marks a significant expansion of the company’s advanced protein and gene platforms and is designed to provide high quality, fast turnaround on products required for new vaccines and therapeutics development and innovations in life sciences.
Supported by the Singapore’s Economic Development Board (EDB), the new production site will support the Asia Pacific region and complements the current production sites in the United States and China.
The opening ceremony was held in a virtual setting inaugurated by Minister of State for Trade and Industry, and Culture, Community and Youth, Alvin Tan and accompanied by Senior Vice President and Head, Healthcare, Singapore Economic Development Board (EDB), Ms Goh Wan Yee.
During the ceremony, GenScript and Diagnostics Development (DxD) Hub, a national platform hosted by the Agency for Science, Technology and Research (A*STAR), signed a memorandum of understanding (MoU) to explore collaborations to build manufacturing capabilities in Singapore.
The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang building. The cutting-edge facility in Singapore features a high throughput platform and proprietary technology of GenScript’s protein production to provide higher yield with a shorter turnaround time.
“This is a significant milestone for us as we strengthen our presence in the vibrant and innovative ecosystem in the Asia Pacific, Singapore. The new manufacturing facility will be a regional innovation and excellence hub in the Asia Pacific and increase the productivity of custom protein manufacturing,” said Johnson Wang, President of GenScript Asia Pacific Division.
Dr Ray Chen, President of Life Science Group, GenScript Biotech Corporation, said: “Singapore , the home to GenScript’s Asia Pacific headquarters, it is also a strategic location for us to expand our manufacturing capability to support the fast-growing biotechnology industry.
“With the strong support from EDB, our new facility aims to be the center of a solid regional network to catalyse more collaboration, ultimately spurring more innovation and breakthrough life science.”
Goh said: “GenScript’s decision to set up its new production site and business hub in Singapore is testament to our robust manufacturing infrastructure, R&D and innovation ecosystem, a strong base of biotech talent, and our excellent connectivity to the Asia-Pacific region,” she said.
